Iterative Health
Iterative Health operates an AI-enabled, community-embedded clinical research site network of 100+ sites serving pharmaceutical sponsors and CROs across gastroenterology, hepatology, obesity, and cardiology, combining FDA-cleared SKOUT AI polyp detection, AI-ES scoring, and centralized operations that outperform industry trial benchmarks.
- Company typePrivate
- Founded2021
- HeadquartersCambridge, United States
- Headcount251–500
- GTM typeB2B
- OfferingServices
What Iterative Health does
Iterative Health (legal entity Iterative Scopes, Inc., founded 2017, headquartered at 675 Massachusetts Avenue, Cambridge, MA) operates an AI-enabled, community-embedded clinical research site network spanning 100+ research sites across North America, Europe, India, and Australia. The company serves pharmaceutical sponsors, biotech firms, and contract research organizations (CROs) that need to execute Phase II-IV trials in gastroenterology, hepatology, obesity, and cardiology, and serves as an operational partner to community specialty practices that want to participate in research without building internal infrastructure. At the center of the offering is a centralized operating layer that provides regulatory documentation, training, budgeting, AI-driven pre-screening, and trial management, combined with proprietary AI capabilities including SKOUT (an FDA-cleared real-time AI polyp detection system), AI-ES and AI-ESe (automated endoscopic scoring for ulcerative colitis developed with Eli Lilly), and machine-learning patient matching built on de-identified endoscopic video and EHR data from across the network. Reported performance metrics include 2x faster site activation, 3-3.4x higher patient enrollment versus published industry benchmarks, 74-day median activation timelines (versus 120-171 day benchmarks), and high-performing endoscopists detecting 1 additional adenoma per 4.5 patients with SKOUT assistance.
The business model rests on three revenue streams: (1) clinical research site network services sold via enterprise agreements to pharma/CRO sponsors, typically multi-year and quote-based, with deal scope set by therapeutic area, enrollment targets, and geographic reach; (2) SKOUT AI device licensing, negotiated annually with gastroenterology practices and ambulatory surgery centers; and (3) patient recruitment services for specific trials, structured as master services agreements (e.g., a $3 million equity-linked recruitment engagement with Palisade Bio for the PALI-2108 ulcerative colitis Phase 2 trial). Go-to-market runs through three channels: enterprise field sales targeting sponsors and CROs, channel/MSO partnerships with major specialty provider networks (GI Alliance and Cardinal Health, One GI and Webster Equity Partners, US Heart & Vascular), and direct licensing of SKOUT to GI practices. The company is venture-backed (approximately $257 million disclosed across Seed/Series A/B/C), led by founder/CEO Jonathan Ng, and has expanded its C-suite through 2025-2026 with a President/CFO hire from GI Alliance, a CMO for Hepatology & Obesity, and a promotion to COO.
Iterative Health firmographics
Firmographics- Name
- Iterative Health
- Legal name
- Iterative Scopes, Inc.
- Website
- https://iterative.health
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- Iterative Health operates an AI-enabled, community-embedded clinical research site network of 100+ sites serving pharmaceutical sponsors and CROs across gastroenterology, hepatology, obesity, and cardiology, combining FDA-cleared SKOUT AI polyp detection, AI-ES scoring, and centralized operations that outperform industry trial benchmarks.
- Ownership category
- akta.pro rank
Iterative Health industry classification
Industry- Product category
- Clinical Research Services
- NAICS
- Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Custom Computer Programming Services (541511), Software Publishers (5132)
- SIC
- Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Site & Investigator Platforms (Site Payments, Feasibility, Activation) (HLACAOAJ)
- akta.pro secondary industries
- Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO), General Gastroenterology (HLAKAEAA), Inflammatory Bowel Disease (IBD) Care (HLAKAEAD), Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF) (HLAGAJAM), AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
Keywords
Where Iterative Health is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Offices5 records
Markets served
Iterative Health business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Clinical Research Site Network Services: Iterative Health generates revenue by providing a network of high-performing clinical research sites to pharmaceutical sponsors, biotech companies, and CROs. The company embeds clinical research infrastructure into community-based physician practices, offering centralized operations, staffing, AI technology, and trial management services. Revenue comes from clinical trial agreements where sponsors pay for site access, patient enrollment, and trial execution performance.
- SKOUT AI Device Licensing: FDA-cleared AI polyp detection technology licensed to gastroenterology practices and ambulatory surgery centers. The company provides the AI software as a device that enhances colonoscopy quality, generating licensing revenue from healthcare providers who adopt the technology for clinical use.
- Patient Recruitment Services: Revenue generated through master services agreements to accelerate patient recruitment for specific clinical trials, such as the partnership with Palisade Bio for their PALI-2108 Phase 2 trial enrollment. Services include AI-powered screening and operational support.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Enterprise clinical trial services with customized scope based on therapeutic area, trial complexity, site network access, and performance requirements. |
| Other | Annual | AI-assisted colonoscopy technology for gastroenterology practices and ASCs. |
Go-to-market motion3 records
Distribution channels3 records
Marketing channels7 records
Iterative Health product offering
Product offeringCore offering
Iterative Health operates a global multispecialty clinical research site network spanning 100+ sites across North America, Europe, India, and Australia, embedded in community-based physician practices for GI, hepatology, obesity, and cardiology trials. The company also develops and commercializes proprietary AI technology, most notably SKOUT® (FDA-cleared real-time AI polyp detection for colonoscopy) and AI-ES/AI-ESe (automated endoscopic scoring systems for ulcerative colitis clinical trials), sold to pharma sponsors, CROs, and healthcare providers.
Product overview
Iterative Health is a healthcare technology and services company offering a unified portfolio centered on accelerating clinical research. The core offering combines a global multispecialty Site Network spanning over 100 research sites with proprietary AI technology. Key products include SKOUT®, an FDA-cleared real-time AI polyp detection device for colonoscopy, and AI-powered clinical trial tools including AI-ES and AI-ESe for automated endoscopic scoring in ulcerative colitis. The company also provides AI-enabled pre-screening technology and centralized operational support services that power the site network model, enabling sponsors to accelerate trial execution across gastroenterology, hepatology, obesity, and cardiology therapeutic areas.
Differentiator
Problem solved
Functional benefit
Brands
- SKOUT: Real-time AI-powered polyp detection technology for colonoscopy procedures, FDA-cleared AI-assisted device for GI care.
Products and services
- SKOUT® Real-Time AI Polyp Detection FDA-cleared real-time AI-powered polyp detection system for colonoscopy procedures that uses advanced computer vision to identify clinically significant lesions and sessile serrated polyps during endoscopy, helping clinicians improve adenoma detection rates. Licensed to gastroenterology practices and ambulatory surgery centers seeking to improve colonoscopy quality and meet ACG/ASGE quality recommendations.
- Iterative Health Site Network (Clinical Research Services) Global multispecialty clinical research network embedded in community care settings, spanning over 100 research sites across North America, Europe, India, and Australia. Provides pharmaceutical sponsors, biotech firms, and CROs with centralized access to high-performing sites for GI, hepatology, obesity, and cardiology clinical trials, delivering 2x faster site activation and 3x higher enrollment rates versus industry benchmarks. Includes centralized operations, expert staffing, regulatory support, budgeting, training, and pre-screening workflows.
- AI-ES (AI Endoscopic Score) and AI-ESe (Extended Endoscopic Score) Machine learning-based systems that automate endoscopic inflammation scoring for ulcerative colitis clinical trials, improving reliability and reproducibility of disease severity assessment compared with manual human-based central reading. AI-ESe is the extended version that characterizes overall burden of inflammation with higher detail. Sold as a clinical trial endpoint technology to pharmaceutical sponsors.
- AI-Powered Patient Recruitment Services Patient recruitment services powered by machine learning algorithms that process de-identified endoscopic videos and EHR data from the 100+ GI community sites to identify eligible clinical trial participants. Delivered through master services agreements to pharmaceutical sponsors, reducing screen failure rates and accelerating enrollment timelines.
Quantifiable outcome
- 2x faster site activation, reducing startup timelines by up to 3 months compared to industry benchmarks
- +5 more outcomes
Companies that use Iterative Health
Customer profileNamed customers8 records
Segments4 records
Ideal customer profiles3 records
Iterative Health technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability9 records
Feature6 records
Iterative Health partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered core, minor and flagship.
- NextStage Clinical ResearchcoreAcquisition of three cardiology research sites in Beaumont, Port Arthur, and Waco, Texas from NextStage Clinical Research. Bourne Partners served as exclusive financial advisor on the transaction. Sites bring experienced cardiovascular research teams, established community provider relationships, and active cardiology trial programs.
- Palisade BiominorPatient recruitment partnership with $3 million investment from Iterative Health affiliate. Palisade Bio sold shares to Iterative Health affiliate and entered master services agreement for patient recruitment support for Phase 2 trial of PALI-2108 in ulcerative colitis.
- US Heart & VascularcoreStrategic partnership to advance community-based cardiovascular research. USHV clinical research sites join Iterative Health's global site network spanning 100+ sites across 3 continents. USHV sites gain access to Iterative Health's centralized operational backbone, end-to-end clinical research operations support, technology innovation, and business development capabilities. Partnership expands Iterative Health beyond GI, hepatology, and obesity into cardiology.
- Eli LillycoreCollaboration on AI-powered endoscopic scoring for ulcerative colitis clinical trials. Partnership developed AI-Enabled Endoscopic Score (AI-ES) and extended AI-ESe, with data presented at ECCO 2025. Collaboration aims to improve reliability and reproducibility of endoscopic outcomes in clinical trials.
- One GIcoreStrategic partnership with One GI (top physician-led MSO and Webster Equity Partners portfolio company) to advance clinical research as a core ancillary service. One GI's network of 34 clinics across 6 states with 13 active research sites becomes exclusive mainstay in Iterative Health's global site network. Collaboration builds on two years of consistent industry-leading results.
- GI AllianceflagshipGI Alliance (a Cardinal Health company and the nation's leading gastroenterology network) formed strategic partnership to expand access to clinical trials across community-based practices. Integration of GIA's 21 active research sites conducting over 80 Phase II-IV trials into Iterative Health's Site Network, creating a combined network of more than 70 locations across US and Europe. Partnership represents a first-of-its-kind alliance to power the largest GI-focused clinical research network.
- TakedacoreAI partnership to improve patient selection, clinical assessments, and treatment pathways for inflammatory bowel disease (IBD) using machine learning. Partnership leverages AI-driven endoscopic assessments to advance patient selection and clinical evaluation in IBD clinical trials. Takeda's goal is evidence-based decision-making on therapy utilization in the real world.
- Crohn's & Colitis FoundationminorPartnership to advance next-generation IBD treatment. Foundation's patient data repository enriches Iterative Health's AI models for GI clinical research, supporting the development of novel therapies for inflammatory bowel disease.
- PfizercoreAI-driven data sharing agreement to advance IBD clinical trials. Agreement deployed artificial intelligence to improve efficiency and accelerate drug development for inflammatory bowel disease.
Scale indicators10 records
Recent moves6 records
Expansion highlights7 records
Iterative Health competitors and assessment
Company assessmentMarket position
Competitive moat6 records
Key highlights7 records
Customer concentration
Iterative Health social profiles
Digital presenceIterative Health compliance and trust
Trust signalCompliance2 records
Iterative Health financial estimates
Financial estimateRevenue estimate
Valuation estimate
Iterative Health leadership team
Management profileNumber of profiles
Profiles8 records
Iterative Health subsidiaries and ownership
Company hierarchySubsidiaries3 records
Iterative Health funding detail
Funding detailFunding overview
Funding rounds10 records
Investors21 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Iterative Health M&A and investment
M&A and investmentM&A
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Iterative Health
What does Iterative Health do?
Iterative Health operates a global multispecialty clinical research site network spanning 100+ sites across North America, Europe, India, and Australia, embedded in community-based physician practices for GI, hepatology, obesity, and cardiology trials. The company also develops and commercializes proprietary AI technology, most notably SKOUT® (FDA-cleared real-time AI polyp detection for colonoscopy) and AI-ES/AI-ESe (automated endoscopic scoring systems for ulcerative colitis clinical trials), sold to pharma sponsors, CROs, and healthcare providers.
Is Iterative Health a public or private company?
Iterative Health is a private company. It is classified as venture growth investor backed and is currently operating.
When was Iterative Health founded?
Iterative Health was founded in 2021. It employs 251 to 500 people.
Where is Iterative Health based?
Iterative Health is headquartered in Cambridge, United States, in the North America region.
How does Iterative Health make money?
Three revenue lines are on record. Clinical Research Site Network Services are the primary driver. The others are SKOUT AI Device Licensing and patient Recruitment Services.
Does Iterative Health have an API?
No public API is recorded for Iterative Health.
What industry is Iterative Health in?
Iterative Health's product category is Clinical Research Services. Its primary akta.pro industry code is HLACAOAJ, Site & Investigator Platforms (Site Payments, Feasibility, Activation), with a secondary code of HLAAALAO, Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays). Its NAICS code is 5417 and its SIC code is 8731.